AbbVie Inc. (NYSE:ABBV)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for ABBV
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- Bert953: #Squeezing stocks... Adding 5 more squeezes and re-posting. Of course some of these are better than others. For example $AAPL is under the 50 & 200dMA's so not something Im interested in RHRN. $ABBV $ALHC $AAPL $FTNT $SPY $FROG $PINS $LUNR $KRMN $INGM $EXEL $DKNG $BA $MSFT $PLTR $RACE $SOUN $SSO $T $QQQ $TQQQ $WGS $WMT $WRAP $V $WAY $MNST $NOW $SMCI $ALAB $JPM
- Bert953: #Squeezing stocks... Adding4 more squeezes and re-posting. Of course some of these are better than others. For example $AAPL is under the 50 & 200dMA's so not something Im interested in RHRN. $ABBV $ALHC $AAPL $FTNT $SPY $FROG $PINS $LUNR $KRMN $INGM $EXEL $DKNG $BA $MSFT $PLTR $RACE $SOUN $SSO $T $QQQ $TQQQ $WGS $WMT $WRAP $V $WAY $MNST $NOW $SMCI $ALAB
- phgruver: Good morning, y'all. Another pleasant day, here in the southeast. A few scattered showers, floating around, but nothing significant. I'm almost hesitant to mention this, but healthcare $XLV seems to be showing some signs of life. In a long term #VALUE portfolio, this might be a good time to add some to you high dividend payers. I added, small, to my $BMY, which pays a 5.18% dividend that is well supported by earnings. $PFE pays 7.33% (with a bit more headline risk) and $ABBV is at 3.23%. I also own some $GSK which pays 4.02%, but, unlike the others, is a bit extended.
- Wolf: @Bridgemate $ABBV Took a starter Friday @ 181. Wishing now I had taken a bigger byte.
- phgruver: The one green spot on my screen, this morning, is $ABBV. They reported a beat on earnings and revenue, and raised 2025 guidance. This has been a good LT investment, since they bought the Botox franchise back in 2019. They also pay a 3.64% dividend, which isn't too shabby....
- Wolf: @phgruver $ABBV I have been watching for an entry. I am a little gun shy after the dive on the open.
- Bridgemate: @Wolf $ABBV Same here, I was ready to pull the trigger and still might
- Wolf: $ABBV up 3rd day. Breaking above downtrend.
- traderbren: Just FYI - $BMY, $GILD, $ABBV, $AMGN -- interesting.... NP
- wjj3: @traderbren $BMY $GILD $ABBV $AMGN !!!I own them all
- Wolf: #Big Pharma Only green I see other than $GLD. $MRK $JNJ $PJE $ABBV $LLY all up.
- traderbren: $NVS, $ABBV - trades - Puts - that I closed out this morning. Gotta take the moolah and run.
- chimper: $ABBV, I'm in with a small loss, but it seems to be consolidating a bit. Thoughts?
- phgruver: @chimper $ABBV I like $ABBV. I've been in it since Sept. 2019, when the stock got body slammed for buying Botox, and I've added a bit as it proved itself over the next 9 months. Currently, it is consolidating around the 20DMA, and I could, realistically, see it pulling back to around $200. The company has reported modest beats, on earnings, all year and pays a 3% dividend, at today's prices. It has been a steady performer the whole time I have owned it. IMHO, this is not a trading stock, but one to acquire as a #LongTermInvestment. Also, it is near the top of it's 52 week range, so it is probably not a good time jump in. You could create a small starter position, and look for opportunities to add on weakness.
- Wolf: $ABBV 8DMA still support. Upper BB seems to be resistance. Set a new 52 week high today. Long small position.
- woodman: $SWTX $LUCD - I'm newly in these two spec biotechs (bought yesterday). $SWTX, an oncology company, is in talks for a buyout. They appear to be advanced talks. Merck KgaA (German company) has been in talks with SWTX and is the lead horse, but there could be other bidders such as $ABBV and $NVS. If it happens, it could happen at any time. $LUCD has an approved medical test called EsoGuard to test for esphageal cancer and related. It is awaiting Medicare approval. That could light a fire, while also raising prospects for private insurance coverage. Big TAM, small market cap. Nice potential set up for a multi-bagger in time. All this said, these are spec trades and biotech is too frequently a soul/wallet crusher, so be warned. If interested, I suggerst performing some research.
- Boogie: $ABBV Has been riding 8EMA up since Feb1. THis must be reason ...Biotech giant AbbVie is getting into the weight-loss space. On Monday, it announced that it had signed a licensing deal worth up to $2.2 billion with Danish company Gubra to bring a long-lasting amylin drug, delivered by injection, to market. The obesity market is growing fast and dominated by GLP-1 drugs from Novo Nordisk (which makes Ozempic and Wegovy) and Eli Lilly (Zepbound and Mounjaro). In a December note to investors, Leerink Partners called amylin “the hottest new mechanism for obesity.” Gubra’s GUB014295 is currently in a phase 1 clinical trial. AbbVie will pay $350 million upfront, with an additional $1.875 billion based on milestones.
- Wolf: $ABBV Have been looking for an entry, but it keeps riding between the 8DMA and the upper BB. Last test of the 8 was on 2/18 when it started a slow breakout.
- Mikev200: $ABBV Nov gap filled
- Mikev200: $ABBV continues filling Nov. gap
-
StockMarketMentor: ...
$AAPL and $INTC reported last night, along with notables $DECK, $TEAM, $VIAV, $BKR, $BOOT, $BZH, and $KLAC. Reporting this morning were $ABBV, $XOM, $CVX, $ETN, $LYB, $CL, $LPG, $CHTR, and $BAH. Most of these names have had normal post-earnings reac ... - Wolf: $ABBV Strong open, near HoD
- phgruver: $ABBV is down about 12% on news that a high profile drug failed phase 2 testing. This seems like an extreme move, to me. One to watch for an oversold bounce?
- gklee01: @phgruver $ABBV Pretty good looking weekly chart. Right at the 50MA.
- Mikev200: $ABBV day 2
- Mikev200: $ABBV ATH earnings this morning
- Mikev200: $ABBV HOD
- phgruver: $ABBV went ex-div, today, trading less the $1.55 dividend, that will be paid on Nov. 15. At today's price, this is a 3.17% yield. This stock is in a slow, steady uptrend. It's not at a great buy point, but you could add here, and expect to make money. This is a long term hold, for me. I'm in from around $68.... :-)
- Mikev200: $ACN $ABT $ABBV nice moves on volume
- phgruver: $ABBV is still running, and pulling $XLV with it. @DavidK: $BA, no, $WFC, yes, $CLF, no. Financials, in gerneral ($XLF) are working, but the other two are in the dog house. Will they recover? Sooner or later, but, in the mean time, there are better places to put your money.
- DavidK: @phgruver $ABBV $XLV $BA $WFC $CLF $XLF $CLF- yep this along with other steel stocks seem to be signally a slowdown in the economy . I will be picking up some clf sometime but that’s the big question , when ? Chart looks like down to 10 . Company had been buying back stock but maybe needs to conserve the cash now .
- phgruver: Healthcare $XLV, and utilities, $XLU are my best performers, so far today. In healthcare I have $ABBV, $BMY, $CVS and $PFE. I would suggest you stay away from $PFE, but the others are cooking! In utilities I have $AEP, $D, $DUK and $SO. I'm not real happy with $D, but the others all have nice charts and pay decent dividends. $AEP, $DUK and $SO are all breaking out from a squeeze and are above the upper Bollinger Band.
- woodman: @phgruver $XLV $XLU $ABBV $BMY $CVS $PFE $AEP $D $DUK $SO - Some additional sectors, perhaps: XLRE, SDY, maybe IHI (but nearing rising resistance), and maybe XLF & GLD/IAU (they are resting today)
- phgruver: @DavidG $PFE Man, I could write a whole blog post about that! Let me try to put it succintly, though. First, $PFE is an established player in a difficult sector with a wide moat to their business. The FDA is a major obstacle to any newcomer! So, ...
- jaeran: @woodman $XLV $XLU $ABBV $BMY $CVS $PFE $AEP $D $DUK $SO
-
StockMarketMentor: ...
$ABBV -- stopped out for a 10.7% gain. Good trade, but momentum is slowing, and the stock is starting to roll over. I'm protecting profits here.
$RYTM -- stopped out at 46.49. Holding at the 50-day moving average. I'm closing this on the ATI l ... - StockMarketMentor: $ABBV -- Raising the suggested stop to 194.10 to lock in a 10.4% gain. The uptrend remains strong, but I don't want to risk allowing a good trade to turn into a not-so-good trade. --Dan
-
StockMarketMentor: ...
Currently $ABBV is the only one that’s active ($PFE got stopped out yesterday for a small loss). I will likely put a few stocks on today to capitalize on any continuation of yesterday’s buying.
Watch for it on Telegram, in the Tradin ... - phgruver: @Henry $UNH I'm in $ABBV, which is also flying high! As it looks right now, healthcare isn't going to be the political football of choice, this election cycle, so it may be "safe" to invest in $XLV components.
- Mikev200: $ABBV green
- Mikev200: $ABBV ATH
-
StockMarketMentor: ...
$ABBV: Down a bit and still in consolidation. We were faked out by the breakout above $175 last week, but the stock is stable and seems to just need more time.
$BAC: Looking for a floor at $42 to complete the second phase of a volatility squeeze ... - phgruver: While I like $ABBV long term, be careful with it RHRN. Earnings will be reported Thur., before the bell. The chart pattern is "constructive", but it is running along the upper Bollinger Band. The relatively close proximity of the price to the 50dma and 200dma is a positive. Also, the dividend, at 3.6%, is attractive but not overwelmingly so.
-
StockMarketMentor: ...
$ABBV wanted to break out yesterday and I want to start a position here. I’ll make it conditional on breaking above yesterday’s intraday high of 175.74, and a stop just below yesterday’s low of 169.51.
$JNJ is on a tear and is ... - wjj3: @StockMarketMentor $XLF $XLV $BAC $PFE $ABBV $JNJ $ $GEHC upward price action is
- Wolf: $ABBV Up 3% on Cowen upgrade and Sionna news. NP
- Wolf: $ABBV Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma. Up 2% on 3.5% normal volume.
- Wolf: $ABBV Broke through a choppy trendline and is back above all the moving averages. Watching for a further breakout or the 50DMA to hold. Long with 170 covered call.
- Wolf: $ABBV Continuing to breakout. May have to roll cc again.
- Wolf: $ABBV IRA #Bottom-Fishing Buy-write stock 160 06/28 STO160 call @ 3.79. BTC today @ 2.08.
- Wolf: $ABBV making a dragonfly off the 200DMA. NP.
- indigo1948: @DAN $ADBE - Dan - good morning. Could you cover $ABBV, $SANM, $DOCU and $CLF. Thank you.
- indigo1948: @DAN - Please look at $PLTR, $CL, $TOL, $ABBV & $SANM. Thank you.
- phgruver: @woodman $LLY $ABBV, $LLY and $MRK are certainly driving $XLV higher!
- Mikev200: $ABBV ATH
- phgruver: @Mikev200 $ABBV I wish I had more, but I can't buy it here.
- BarryC: Hi Everyone!! Hope ya had a great weekend!! If anyone cares, I'm currently #Long: $ABBV, $BX, $GTLB, $IBIT, $MRVL, $MSOS, $NVO, $PATH, $PSTG, $$XBI
- BarryC: Hi Everyone!! Hope all is good in the hood :-) Im currently $Long: $ABBV, $BX, $GTLB, $IBIT, $MRVL, $MSOS, $NVO, $PATH & $PSTG... I'm still staring at $XBI in particular.... Have a great day!!
- BarryC: Hi Everyone!! GM!! I put on a couple new positions yesterday and mentioned them here as I did them... I'm currently #Long: $ABBV, $BX, $EYPT, $GTLB, $IBIT, $MRVL, $MSOS, $NVO & $XBI... #FWIW: I keep hearing that "breath is bad" and as a result we're "overbought"... FOR ME, I will stick to the prices (Charts) and that's ALL I NEED! Anything else is an opinion and we know what they say about those... :-) Stick to ur plan & Lets kick some axx!!
- BarryC: Hi everyone, I'm still pretty light overall... I'm currently #long: $ABBV, $EYPT, $GTLB, $MSOS, & $NVO... I did buy a small starter position in $XBI yesterday afternoon and its my main focus today... Lets kick some axx!! :-)
- BarryC: Hi guys, Im still pretty light... Im currently #Long: $ABBV, $EYPT, $GTLB, $MSOS & $NVO
- phgruver: @BarryC $ABBV $EYPT $GTLB $MSOS $NVO #Long I like $ABBV as a LT hold, but I couldn't buy it RHRN. It pays a 3.62% dividend (at $171.26), and has had a really good run since the first of Dec. I'm long from $68.... :-)
- phgruver: @BarryC $ABBV $EYPT $GTLB $MSOS $NVO #Long I like $ABBV as a LT hold, but I couldn't buy it RHRN. It pays a 3.62% dividend (at $171.26), and has had a really good run since the first of Dec. I'm long from $68, so my rate of return is over 9%..... :-)
- BarryC: Hi Everyone, Hope ya had a great weekend!! I'm fairly light overall and currently #Long: $ABBV, $EYPT, $JNUG, $MSOS, $NVO, $RSP & $XHB As always, I will post anything I do as I go :-)
- BarryC: I bot $ABBV
- indigo1948: @BarryC $ABBV - longer term hold for me = peaks and valleys - now a slight peak.
- Boone.ruth: @BarryC $ABBV thanks for this one
- BarryC: @Boone.ruth $ABBV :-) <3
- woodman: $ABBV @BarryC - ABBV For Skyrizi & Rinvoq, combined 2027 revenues are now expected to be >$27B, ~$6B increase vs previous guidance. for Ubrelvy & Qulipta, combined peak revenue is expected to be >$3B, an increase of ~$1B compared to previous guidance.
- BarryC: $ABBV Worth Watching
- BarryC: $ABBV earnings tomorrow, my bad!!!
- joelsg1: $EOLS Up after strong E, half the price of Botox for those who inject neurotoxins, so pure play alternative to $ABBV which owns Botox, Np.
- phgruver: @oldtimer The only thing green for me was $ABBV. Just now $IBM also went green. That really isn't telling me anything, other than this is a really tough market....
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- Wolf: $ABBV Broke out yesterday on 2x normal volume. Up slightly today. Started a small position.
- Wolf: @Onthemark $PFE $ABBV is breaking out as well. Tagged the upper BB on decent volume. No position.
- Wolf: $ABBV Back above all MA's. Took a small position @ 151.63. Not a real good entry, but it continues to move higher on higher than average volume.
- Wolf: $ABBV Clean break through the 200 DMA and so far not looking back.
- phgruver: Possible bounce play with $PFE. The dividend is $0.41/qtr, which equates to 5.67% at this price. Unless you expect $PFE to totally collapse, this is a pretty good #VALUE entry for a solid income in a long term portfolio. $XLV, in general, is down near lows, although $LLY and $NOV seems to be bucking that trend. (I also own $ABBV and $BMY for income)
- Wolf: $ABBV Looking kind of frisky on news they are buying ImmunoGen....
- woodman: @dmurphy68 $ARDX - I agree with that too. For illustration purposes, $IMGN went from a $3.70 stock in April this year to $29 yesterday on an announced buyout by $ABBV for over $10 billion. It's a bit of apples and oragnes (IMGN focuses on antibody-drug conjugate (ADC) technology to treat cancer), I know, but $ARDX is a $1 Billion company right now. If ARDX is bought, IMO, it will be for much more than current price and even that $9 price.
- dmurphy68: @woodman $ARDX $IMGN $ABBV $29 would be a very welcome development. I would not be disappointed (or surprised, really) if it went for even half that.
- woodman: $XBI continues up. All my little Bios are working today. Has the worm finally turned for biotech (we'll see at the overhead 200d, I suppose)? $IMGN deal (bought by $ABBV for $10 billion) is helping today.
- sgiseller: $ABBV anyone tracking this? Looks to have a big pipeline but has been taken to the woodshed this year
- traderbren: #Shorts - closed out my $UNH short this morning, but still holding my $ABBV short -- both via Puts.
- wjj3: $ABBV triple bottom at 132 ish and break thru resistance at 140 looking then for 160 with 4.4% pretty fair risk reward
- phgruver: Healthcare, $XLV, is holding support and showing promise. All my healthcare stocks, $ABBV, $BMY, $CVS, $PFE are looking good right here.
- phgruver: I like the way $XLV is setting up on the daily chart. It's above the 200dma, holding support at the 50dma and trading just above the lower Bolenger Band. To me, it looks poised to move higher over the next couple of weeks. $XLV has nearly 20% of it's assets in $UNH and $JNJ, and another 5% in each of $LLY, $ABBV, $PFE and $ABT. Not surprisingly, all those underlying stocks have charts that look pretty similar. I own several stock in this space, (which I don't trade) and use options on $XLV to add to my returns. Many of these stock are good dividend payers, which pay well in the long term, if you get good entries.
- lauralynnee: $ABBV is approaching within a few points of ATH, 50/200 cross a few days back, had made nice run up and has settled down and sitting on 8EMA. Could be making a handle on the massive cup...
-
Rockstar: ...
The $DIA and $IWM continue their strength with some strength in more than a couple ETF's. The ETF's that I am looking at long positions include $TAN, $XLF, $XLE, $XLB, $XLI, $XLP, $XLV, $XME,and $IYT. Of these, I am hesitant on the $XLE with oi ... -
Rockstar: ...
Specific stocks I am looking at for longs are in the health care sector with $JNJ,$ABBV,$VRTX,$MRK,$CI and $UNH on that list. I am also looking at $PEP $COST,$WMT, $TMUS (already long), $NUE $GS and $AXP for longs in the $XLV and $XLF sectors. ... - phgruver: @vcondry $LLY Healthcare, $XLV, in general is getting hammered. $BMY is my biggest looser, today, but $ABBV, $CVS, and $PFE are all down biggly. I can't find any news either, but there was a big run up going into the election, so maybe just a bit of profit taking, although down 4% to 5% seems a bit extreme for basic profit taking.....
- vcondry: @phgruver $LLY $XLV $BMY $ABBV $CVS $PFE did find a report that early this morning some fake verified Twitter accounts including one for Lilly that was not legit said "Insulin is now Free" which got spread everywhere causing a big hit but other then that yes it seems pretty excessive for $JNJ $LLY etc Like I said its been a pretty decent buying opportunity before but who knows.
- traderbren: $ABBV - we could see a gap fill trade with a move above 149. Long from below.
- phgruver: $ABBV is trading down $7 (about 5%) after being downgraded by SVB Leerink. Actually, it wasn't a downgrade, but a lowering of their price target to $135. Consequently, $ABBV is now trading just above that lowered $135 price target. Earnings continue to be good, and the $5.64 dividend appears to be safe. With a P/E of 19.97, the stock would appear to be fairly valued. Not a screaming buy RHRN, but one to watch for a long term investment. At the current price, the dividend yield is right at 4%, what Cramer calls "an accidental high yielder." If the price stabilizes right here, it could be a strategic buy.
- phgruver: @traderbren $LLY Right now, in health care/pharma, ($XLV) I'm holding $ABBV, $BMY, $CVS and $PFE. All are doing OK, but I couldn't recommend buying or adding RHRN. Everything seems to be under pressure. Time to go do something else. It's a waste of time to sit here watching the market flounder.
- bwcarnation1: @scottrades $VRTX $ABBV holding up also but just under the 200d now. Nice 3.96% div.
- Roadrunner: $ABBV sitting on 50 day weekly - hasn't dropped below that since late 2020 - looks like a double bottom on the daily - up 3% today
- sgiseller: $MRK $LLY $ABBV starting very small positions in all
- Margi1983: $ABBV. Sitting at the 50..Volatility squeeze... Profitable, good sales growth, good earnings growth, 3.8% Divi. What's not to like? NP but watching
| Stock Price | $218.34 |
| Change | -0.85% |
| Volume | 4,418,750 |
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.
Request Video of ABBVAlready a member? Sign in here.
Past Month
Leading Peers
-
$5.37 37.25%
-
$39.62 25.90%
-
$19.93 12.77%
Past Month
Lagging Peers
-
$28.61 -74.29%
-
$18.94 -33.74%
-
$5.39 -13.52%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!